Zomepirac has been shown to be rapidly and completely absorbed after oral administration to man. Urinary excretion is the principal route for removal of zomepirac and its metabolites in man and in animals. Zomepirac is highly bound to plasma protein. The pharmacokinetics of zomepirac after single and multiple doses in man can be adequately described by a two-compartment oral absorption model. There is a linear relationship between dose and peak plasma concentration, AUC, and urinary excretion of zomepirac. The bioavailability of zomepirac was unaffected by single or repeated doses of antacid. The rhesus monkey has been shown to be a good predictive animal model for zomepirac's metabolism and pharmacokinetics in man, with glucuronidation found to be the principal route of metabolism in both species.
[1]
W. Wu,et al.
The metabolism of zomepirac sodium. II. Isolation and identification of the urinary metabolites in rat, mouse, rhesus monkey, and man.
,
1980,
Drug metabolism and disposition: the biological fate of chemicals.
[2]
R. Nayak,et al.
Zomepirac kinetics in healthy males
,
1980,
Clinical pharmacology and therapeutics.
[3]
K. Ng,et al.
Determination of zomepirac in plasma by high-pressure liquid chromatography.
,
1979,
Journal of chromatography.
[4]
B. H. Migdalof,et al.
Renal handling of zomepirac sodium (McN-2783-21-98) in the rat.
,
1979,
The Journal of pharmacology and experimental therapeutics.